Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.
about
A novel volume-age-KPS (VAK) glioblastoma classification identifies a prognostic cognate microRNA-gene signatureAntiangiogenic therapy for high-grade gliomaAnti-angiogenic therapy for high grade gliomaBoron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potentialCilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathwayRadiation and concomitant chemotherapy for patients with glioblastoma multiformeMolecular biology of high-grade gliomas: what should the clinician know?Systematic review of supportive care needs in patients with primary malignant brain tumorsPolifeprosan 20, 3.85% carmustine slow release wafer in malignant glioma: patient selection and perspectives on a low-burden therapyGlioblastoma multiforme: emerging treatments and stratification markers beyond new drugsThe future role of personalized medicine in the treatment of glioblastoma multiformeEpidemiologic and molecular prognostic review of glioblastomaPhase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.Treatment of glioblastoma in elderly patients.Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaginAn individual patient data meta-analysis on characteristics, treatments and outcomes of glioblastoma/ gliosarcoma patients with metastases outside of the central nervous system.The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group sLoss of NOTCH2 positively predicts survival in subgroups of human glial brain tumorsSurvival following CyberKnife radiosurgery and hypofractionated radiotherapy for newly diagnosed glioblastoma multiforme.Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients.Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients treated with standard chemoradiotherapy.Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.Recursive partitioning analysis of prognostic factors in WHO grade III glioma patients treated with radiotherapy or radiotherapy plus chemotherapy.Comparison of T2 and FLAIR imaging for target delineation in high grade gliomasDoes age really matter? Radiotherapy in elderly patients with glioblastoma, the Munich experience.Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trialValidation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastomaRadiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era.Age as an independent prognostic factor in patients with glioblastoma: a Radiation Therapy Oncology Group and American College of Surgeons National Cancer Data Base comparison.Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas.Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis.Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004.Low levels of Human Cytomegalovirus Infection in Glioblastoma multiforme associates with patient survival; -a case-control study.Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial.Stratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccination.Impact of age and co-morbidities in patients with newly diagnosed glioblastoma: a pooled data analysis of three prospective mono-institutional phase II studies.The efficacy of temozolomide for recurrent glioblastoma multiforme.The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenograftsSurgical resection of malignant gliomas-role in optimizing patient outcome.α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial.
P2860
Q21560781-4E543AEA-6EAD-455D-BE8F-6457AC2BD3E4Q24193485-24A4475F-053E-44D4-92E8-E37B366E708BQ24240185-9C2FBA0B-B70F-4729-AA12-371BDAAF2DCFQ24628726-17A663FD-AA58-4769-A765-F4981482ED0FQ24647759-9A434EBF-FA71-4CA1-82C6-706260201FCCQ26827957-A259708D-107C-40FD-B0C0-CF7E6551A260Q27009190-02B954E6-218F-44D7-8171-CDF3375D7F13Q27012547-3A5B6301-DCE6-4B75-BCB8-133DAC440C4DQ28078486-B6368970-D8B6-49F6-B7A5-83A02B5117BEQ28082603-5B49B863-4DAE-4166-A2FB-42A9BE33D222Q28391635-55721868-DB59-48C4-AD3C-74B390B4DD76Q28395302-CF69A702-0A07-47CD-BED8-E498E22D4C9AQ30437778-F0B0E2AB-8A5C-458A-99ED-6AD2D2816EA3Q30838145-19AF5595-11E0-4856-802E-555D5E8E7108Q30871297-F446D183-424B-4EF0-82A3-A6FB0FEDDA84Q30929161-D9F6728D-4EFB-4B96-949B-ACDBD30CCF1CQ31117641-A52996CF-0948-4AAC-ADB0-5C611536B899Q33288968-DDDEA0DC-AAAB-48A3-AFBB-B61597225144Q33333892-821BAF29-7F47-42ED-8D5F-4EC98DA12E85Q33356349-04AF6C65-A00B-4B7B-AA9E-C691811ADDCAQ33400189-95CFAFF6-8300-4072-B23B-DF426F871923Q33410196-5E758916-EE7C-4D5E-8E40-BD70F80B995FQ33519196-5C5D7152-EF16-45B0-AC0A-6A95BE5CAE37Q33527143-DEE508D7-5E85-4124-8D94-48DB4F7AA85DQ33612877-3CA103C5-8013-4FEB-83FC-5E1A12E71FE9Q33684972-88508EBE-05CA-4F67-B143-1A1BDAA95D15Q33708309-66A13D90-D24A-4570-975C-C7689810BE42Q33779136-8CE90A78-AB31-4D62-BF68-1D3C9DDF1E6BQ33790042-4E4B4ABA-3FB3-4726-A907-F75776E17629Q33973844-FA6A2994-62BD-4A1B-8498-844AED65E06BQ34048935-49440CDE-EAC3-408D-9841-CA9AF6FF6475Q34132971-AE282407-88A2-496A-A51E-CA519963529EQ34198365-3C969B5D-5834-4D3D-B9CD-27B82B77F75BQ34242939-31701731-69F0-4247-935F-9EFA81DE21D0Q34260758-4C1BEA96-02E7-4C2D-8A03-BFFEE63530E2Q34295064-4187D35E-D3FA-46F2-9729-CD48A9FE1F34Q34297519-50E910D2-90B9-4692-865D-B10B69F6FF18Q34303312-00AEBECE-66D5-48EF-8685-E25D41A9D3B5Q34324963-E7041AEA-02E3-420B-85B9-7BBFBD38690CQ34523918-012826F7-4818-4616-8834-192F82E140A2
P2860
Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Radiotherapy and temozolomide ...... E3 phase III randomized trial.
@ast
Radiotherapy and temozolomide ...... E3 phase III randomized trial.
@en
type
label
Radiotherapy and temozolomide ...... E3 phase III randomized trial.
@ast
Radiotherapy and temozolomide ...... E3 phase III randomized trial.
@en
prefLabel
Radiotherapy and temozolomide ...... E3 phase III randomized trial.
@ast
Radiotherapy and temozolomide ...... E3 phase III randomized trial.
@en
P2093
P356
P1476
Radiotherapy and temozolomide ...... CE3 phase III randomized trial
@en
P2093
Anouk Allgeier
Barbara Fisher
Denis Lacombe
Gregory Cairncross
Jüergen Curschmann
Michele Reni
René-Olivier Mirimanoff
Roger Stupp
Rolf-Dieter Kortmann
Salvador Villa
P304
P356
10.1200/JCO.2005.04.5963
P407
P577
2006-06-01T00:00:00Z